Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

  • ID: 4530843
  • Clinical Trials
  • Region: Global
  • 1556 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • MORE
Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

Summary

The clinical trial report, “Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Multiple Myeloma (Kahler Disease)
  • Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
  • Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy
  • Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting
  • Jan 16, 2018: Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma
  • Jan 08, 2018: Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma
  • Jan 02, 2018: Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma
  • Dec 21, 2017: BioLineRx Announces Initiation of Phase III GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
  • Dec 18, 2017: Poseida Therapeutics Announces First Patient Treated in Phase I Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients With Multiple Myeloma
  • Dec 12, 2017: DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
  • Dec 12, 2017: Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies
  • Dec 12, 2017: Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple
  • Dec 11, 2017: PharmaMar shows new data on plitidepsin for the treatment of multiple myeloma at ASH annual meeting
  • Dec 11, 2017: TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
  • Dec 11, 2017: New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
  • Dec 11, 2017: Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
  • Dec 11, 2017: Affimed Presents Preclinical Data on AFM26 at American Society of Hematology (Ash) Annual Meeting and Exposition 2017
  • Dec 10, 2017: Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
  • Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting
  • Dec 07, 2017: Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
  • Dec 07, 2017: Sanofi explores combination treatments for multiple myeloma in new late-stage trials
  • Dec 05, 2017: U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma
  • Nov 29, 2017: Bristol-Myers Squibb to Present New Data on Multiple Myeloma Drug Elotuzumab at the 59th Annual Meeting & Exposition of the American Society of Hematology
  • Nov 29, 2017: Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About
  • Contact
  • Disclaimer
  • Source
List of Tables
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
List of Figures
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Methodology 1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Celgene Corp
  • Johnson & Johnson
  • Takeda Pharmaceutical Co Ltd
  • Amgen Inc
  • Novartis AG
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Merck & Co Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll